This protein carries an Avi tag (Avitag™) at the N-terminus, followed by a human IgG1 Fc tag.
The protein has a calculated MW of 62.1 kDa. The protein migrates as 65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human FGL1, Avitag,Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human LAG-3, Llama IgG2b Fc Tag, low endotoxin (Cat. No. LA3-H525c) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGL1, Avitag,Fc Tag (Cat. No. FG1-H82F4) with a linear range of 0.156-5 μg/mL (QC tested).
Loaded Biotinylated Human FGL1, Avitag,Fc Tag (Cat. No. FG1-H82F4) on SA Biosensor, can bind Human LAG-3, Fc Tag (Cat. No. LA3-H5255) with an affinity constant of 4.12 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
FACS analysis shows that Biotinylated Human FGL1, Avitag,Fc Tag (Cat. No. FG1-H82F4) can bind to 293T cells overexpressing human LAG3. The concentration of Human FGL1 is 10 μg/mL (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.